DM Stock Watch15 Jul 2021 07:02
Pharmaceuticals services provider Open Orphan made gains after it reported a double dose of good news.
The AIM-listed group’s Dutch arm, Breda, has clinched a £765,000 contract to assist an unnamed existing client with clinical trials.
And the UK government has expanded a Covid study Open Orphan is working on – alongside the Vaccine Taskforce, Imperial College London and the Royal Free London Hospital – which will recruit around 20 volunteers.
Open Orphan did not say how much more it would earn from the extension. Shares rose 3 per cent, or 0.75p, to 26p.